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Abstract
Background:  Brahma (BRM) is a key component of the multisubunit SWI/SNF complex, a
complex which uses the energy of ATP hydrolysis to remodel chromatin. BRM contains an N-
terminal polyglutamine domain, encoded by a polymorphic trinucleotide (CAA/CAG) repeat, the
only known polymorphism in the coding region of the gene (SMARCA2). We have examined the
association of this polymorphism with schizophrenia in a family-based and case/control study.
SMARCA2 was chosen as a candidate gene because of its specific role in developmental pathways,
its high expression level in the brain and some evidence of its association with schizophrenia
spectrum disorder from genome-wide linkage analysis.
Results: Family-based analysis with 281 complete and incomplete triads showed that there is no
significant preferential transmission of any of the alleles to the affected offspring. Also, in the case/
control analysis, similar allele and genotype distributions were observed between affected cases (n
= 289) and unaffected controls (n = 273) in each of three Caucasian populations studied: French
Canadian, Tunisian and other Caucasians of European origin.
Conclusion: Results from our family-based and case-control association study suggest that there
is no association between the trinucleotide repeat polymorphism within SMARCA2  and
schizophrenia.
Background
The SWI/SNF complex is a 2MDa, multi-subunit complex
that uses the energy of ATP hydrolysis to disrupt nucleo-
some structure thereby increasing accessibility of tran-
scription factors to their specific sites on DNA and
histones. It is well conserved, with homologous com-
plexes isolated from yeast, Xenopus, Drosophila and
mammals [1]. SWI/SNF complexes purified from mam-
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malian cell lines have been found to be heterologous with
respect to their subunit composition, containing between
9–12 subunits [2]. However, each complex contains
Brahma (BRM), a DNA-dependant ATPase, or the related
protein BRG1. The precise subunit composition of the
complex appears to confer functional specificity via pro-
tein-protein interactions with specific transcription fac-
tors. BRM has been shown to be specifically required for
activation by the androgen receptor [3]. In addition, BRM
and not BRG1, interacts specifically with CBF-1 and
ICD22, two components of the Notch signalling pathway,
a pathway that controls cell fate commitment in several
developmental processes [4]. Studies in mice have shown
that high levels of BRM, in comparison to levels of BRG1,
are present in brain tissue of the animals [5].
BRM is encoded by the SMARCA2 gene. It is a member of
the large, diverse SMARC (SWI/SNF-related, matrix-asso-
ciated, actin-dependant regulator of chromatin) family.
The only polymorphism within the encoding region of
this gene is a stable, polymorphic trinucleotide repeat. We
have carried out a case/control and family-based study to
examine the association of this polymorphism with schiz-
ophrenia (SCZ).
Investigating SMARCA2 as a candidate gene for SCZ, is
plausible for several reasons. First, genome-wide expres-
sion analysis of a post-mortem section of the dorsolateral
prefrontal cortex of schizophrenia patients showed that
SMARCA2 (also referred to as hSNFa) was upregulated
1.42-fold relative to non-affected controls [6]. Even
though this upregulation of SMARCA2 has not been con-
firmed in other studies, several groups have demonstrated
significant differences in mRNA levels in schizophrenic
patients relative to controls. Gene expression profiles
using post-mortem brain tissue (entorhinal cortex layer II
stellate neurons) showed that 14% of the genes were up-
regulated while 9% were down-regulated more than two-
fold in the SCZ group relative to controls [7]. These results
could be an indication that a global regulator of transcrip-
tion may be involved in SCZ. BRM is one such global tran-
scription regulator. BRM appears to be involved in the
regulation of transcription (activation as well as repres-
sion) of a subset of genes. Genome-wide analysis, follow-
ing deletion of SWI2 (the yeast homolog of BRM),
showed that 1% of the 6,000 genes tested displayed more
than a 3-fold change in mRNA levels, with some genes
being up-regulated and others down-regulated [8,9].
A second reason why an association between BRM and
schizophrenia is plausible is that BRM appears to play an
important role in cell development in general, and neuro-
nal differentiation in particular and SCZ is believed to be
a neurodevelopmental disorder [10]. Unlike BRG1, where
levels are relatively constant in all cells, the cellular con-
centration of BRM increases during cell differentiation.
Studies with neural cell cultures showed that BRM expres-
sion increased during differentiation from neural precur-
sor cells to neural cells [11]. Kondo and Raff [12] provide
evidence that the conversion of oligodendrocyte precursor
cells to neural stem cells required the recruitment of BRM.
Further, BRM has been shown to strongly associate with
CBF-1 and ICD22, two components of the Notch signal-
ling pathway which play a key role in cell fate commit-
ment during development [4].
Finally studying BRM as a candidate gene is supported by
some linkage studies. SMARCA2 is located on chromo-
some 9p22.3. Genome scan meta analysis indicated that
region 9p22.3-21.1 demonstrated significant linkage (p <
0.01) with a schizoaffective-bipolar and bipolar-I disease
model [13].
Results and discussion
BRM encapsulates several distinct domains including a
polyglutamine domain, the DNA-dependant helicase
domain and the bromodomain. The N-terminal poly-
glutamine domain is well conserved in mammals with
Table 1: Summary of subjects used in the family-based study
No of families No of triads
Families with one 
affected individual
Families with more than 
one affected individual
Total Complete triad Incomplete triad* Total
French Canadian 41 0 41 13 28 41
Tunisian 24 12 36 52 2 54
Other Caucasian of European origin-1 58 1 59 28 35 63
Other Caucasian of European origin-2 113 5 118 89 34 123
Total 236 19 255 182 99 281
* Incomplete triads include families with missing parent(s).
"Other Caucasian of European origin-1" included Caucasian triads (excluding French Canadian triads) recruited from Montreal and Ottawa.
"Other Caucasian of European origin-2" included Caucasian triads recruited from Hungary and France.BMC Genetics 2006, 7:34 http://www.biomedcentral.com/1471-2156/7/34
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glutamine-rich regions also present in the homologous
Drosophila Brahma and Saccharomyces cerevisiae Swi2/
Snf2 proteins (Figure 1). BRM is well conserved with the
only known polymorphism within the coding region of
the gene (SMARCA2) being a trinucleotide repeat (CAA/
CAG) polymorphism. The most commonly occurring
allele, corresponding to 32 trinucleotide repeats (181 bps,
according to Genotyper® analysis) was designated the "0"
allele. The two next most commonly occurring alleles
were designated -1 (178 bps) and +1 (184 bps). Rare alle-
les -7, -5, +2, +3, and +4, having an allele frequency less
than 0.01, were also obtained. Due to the problems that
can arise in the cross-tabulation, since these cells had less
than 5 cases each, the alleles were grouped for the statisti-
cal analyses- alleles -7, and -5 were grouped with the -1
allele and +2, +3, and +4 were grouped with the +1 allele.
Case/control analysis was carried out to compare the
allele and genotype frequency of the trinucleotide repeat
polymorphism within three Caucasian populations:
French Canadian, Tunisian and other Caucasians of Euro-
pean origin. Similar allele and genotype distributions
were observed between affected cases and unaffected con-
trols in each of these three populations (Tables 3 and 4).
Table 2: Summary of subjects used in the case-control analysis
Case Control
Cases included in family-based study* Isolated cases† Total
French Canadian 41 59 100 102
Tunisian 24 43 67 46
Other Caucasian of European origin-1 58 64 122 125
Total 123 166 289 273
* Subjects from families having more than one affected individual were not included in the case/control study (please refer to Table 1). Only 
unrelated cases and controls were used for this analysis.
† Isolated cases were those subjects for whom parent DNA samples were not available.
CLUSTAL W (1.82) multiple sequence alignment of the polyglutamine domain of mammalian BRM with the P/Q rich region in  D. melanogaster and S. cerevisiae Figure 1
CLUSTAL W (1.82) multiple sequence alignment of the polyglutamine domain of mammalian BRM with the P/Q rich region in 
D. melanogaster and S. cerevisiae. Sequence alignment between BRM from Homo sapiens [GenBank: NP_003061.3], Macau 
mulatta [GenBank: AAV67666.1], Mus musculus [GenBank: NP_035546.2], Rattus norvegius [GenBank: NP_001004446.1], D. 
melanogaster [GenBank: P25439] and the homologous SNF2p from S. cerevisiae [GenBank: NP_014933.1] was conducted.
BRM(Homo sapiens)        ARGQPLPETLQLAVQGKR-----------------TLPGLQQQQQQQQQQ 225 
BRM(Macau mulatta)       ARGQPLPETLQLAVQGKR-----------------TLPGMQQQQQQQQQP 61 
BRM(Mus musculus)        ARGQPLPETLQLAVQGKR-----------------TLPGMQQQQQQQQQQ 225 
BRM(Rattus norvegius)    ARGQPLPETLQLAVQGKR-----------------TLPGIQQQQQQQQQQ 225 
BRM(D. melanogaster)     ARNKPISMQMQQALQAAQQQPPPGPPIGPPGAPGGPPPGSQHAGQPPVPP 242 
SNF2p(S. cerevisiae)     LQEHNIQDSNVMPGSQIN----------------SPMPQQAQMQQAQFQA 218 
BRM(Homo sapiens)        QQQQQ---------------QQQQQQ------QQPQQQP---PQPQTQQQ 251 
BRM(Macau mulatta)       QQQQQ---------------QQQQ----------PQQQP---PQPQTQQQ 83 
BRM(Mus musculus)        QQQQQ---------------QQQQQQQQQQQPQQPQQQAQAQPQQQQQQQ 260 
BRM(Rattus norvegius)    QQQQQ---------------QQQPQQ-----PQQPQQQTQAQPQQQQQQQ 255 
BRM(D. melanogaster)     QQQQQPPPSAG-----TPPQCSTPPASNPYGPPVPGQKMQVAPPPPHMQQ 287 
SNF2p(S. cerevisiae)     QQAQQ---------------AQQAQQAQQAQARLQQGRRLPMTMFTAEQS 253 
BRM(Homo sapiens)        QQP-ALVNYNRPSGPGPEL--SGPSTPQKLPVPAPGGRPSPAPPAAAQPP 298 
BRM(Macau mulatta)       QQ------------------------------------------------ 85 
BRM(Mus musculus)        QQP-ALVSYNRPSGPGQELLLSGQSAPQKLSAPAPSGRPSPAPQAAVQPT 309 
BRM(Rattus norvegius)    QQPPTLVSYNRPSGPGQELLMTAQNTQRKLSAPAPSGRPSPAPPAATQPT 305 
BRM(D. melanogaster)     GQPLPPQPPQVGGPPPIQQQQPPQQQQQQSQPPPPEPHQHQLPNGGKPLS 337 
SNF2p(S. cerevisiae)     ELLKAQITSLKCLVNRKPIPFEFQAVIQKSINHPPDFKRMLLSLSEFARR 303 BMC Genetics 2006, 7:34 http://www.biomedcentral.com/1471-2156/7/34
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The alleles in the affected and non-affected populations
were in Hardy-Weinberg equilibrium, calculated by con-
sidering each allele in combination with every other
allele. The family-based association analysis (bi-allelic
mode; additive model) showed that none of the alleles
were preferentially transmitted/under-transmitted to the
affected offspring (Table 5). A minor under-transmission
of the -1 allele (p = 0.034) was observed. However this
effect was not significant when corrected for multiple test-
ing.
These results suggest that there is no association between
the trinucleotide repeat polymorphism within SMARCA2
and schizophrenia. Although all subjects included in the
study were carefully diagnosed according to DSM criteria,
as having schizophrenia or schizoaffective disorder, one
cannot exclude the phenotypic diversity that is inherent to
the disorder. For example, within our French Canadian
group of affected subjects, 70.7% were diagnosed with
paranoid schizophrenia, 5.05% with the disorganized
type, 2.02% with schizoaffective disorder and 22.22%
with undifferentiated schizophrenia. There has been con-
siderable discussion recently that in studying the genetics
of schizophrenia and complex psychiatric disorders, in
general, that it is necessary to examine suitable endophe-
notypes within the disorder rather than to examine the
disorder as a whole [17-19]. It remains important there-
fore to examine the association of this trinucleotide repeat
polymorphism within SMARCA2 with specific endophe-
notypes resulting from neurodevelopmental deficits,
given the importance of BRM in development and neural
development in particular. Also given the minor effect
detected with the family-based association study, it may
be important to re-examine this polymorphism with a
larger sample size.
This study also offers a step forward in understanding the
polyglutamine domain within BRM. Although BRM has
been shown to be important in transcriptional regulation,
little is known about the role of the polyglutamine
domain. In the populations we have studied, we have not
observed an expansion of the trinucleotide repeat region,
even though the number of glutamines (32) is close to the
pathogenic threshold of ~35–40 glutamines [20]. The tri-
nucleotide repeat appears therefore to be stable, though
polymorphic. We sequenced the trinucleotide repeat in six
individuals, two each being homozygous for the -1, 0 and
+1 alleles. The sequence encoded by this domain, in the 0
allele, is -Q23-P- Q3 -P2 -Q- P-Q-. The sequence of the -1
allele was -Q22 -P- Q3 -P2 -Q- P -Q- while the sequence of
the +1 allele was -Q24 -P- Q3 -P2 -Q- P -Q-. It therefore
appears that the terminal CAG repeat in the first block of
CAA/CAG repeats is the polymorphic site, at least in the
individuals studied. This is consistent with results
obtained in examining the different alleles at this locus in
an Indian population [21]. Further functional studies
would be important to assess the role of this poly-
glutamine domain in protein-DNA and protein-protein
Table 4: Trinucleotide repeat polymorphism genotype frequency, comparing cases and controls within each of the three populations 
tested
Genotype French-Canadian Tunisian Caucasian of European origin
Case (n = 100) Control (n = 102) Case (n = 67) Control (n = 46) Case (n = 122) Control (n = 125)
-1,0 0.21 0.25 0.19 0.2 0.15 0.18
0,0 0.74 0.75 0.73 0.7 0.83 0.78
0,+1 0.05 0.01 0.07 0.11 0.02 0.04
χ2 = 3.02, df = 2, p > 0.1 χ2 = 0.41, df = 2, p > 0.5 χ2 = 0.91, df = 2, p > 0.5
Table 3: Trinucleotide repeat polymorphism allele frequency, comparing cases and controls within each of the three populations 
tested
Allele French-Canadian Tunisian Caucasian of European origin
Case (n = 100) Control (n = 102) Case (n = 67) Control (n = 46) Case (n = 122) Control (n = 125)
-1 0.11 0.15 0.1 0.11 0.08 0.1
0 0.87 0.85 0.86 0.84 0.91 0.88
+1 0.03 0.01 0.04 0.05 0.01 0.02
χ2 = 3.9, df = 2, p > 0.1 χ2 = 0.2, df = 2, p > 0.5 χ2 = 1.29, df = 2, p > 0.5BMC Genetics 2006, 7:34 http://www.biomedcentral.com/1471-2156/7/34
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interactions. This may be informative particularly since
this domain appears to be a conserved domain in BRM,
which itself is a well conserved regulator of transcription.
Conclusion
Results from our family-based and case-control associa-
tion study suggest that there is no association between the
trinucleotide repeat polymorphism within SMARCA2 and
schizophrenia.
Methods
Subjects
Subjects diagnosed with schizophrenia or schizoaffective
disorder, their families and unrelated healthy controls
were recruited from three populations: Tunisian, French
Canadian and other Caucasians of European origin.
Patients were diagnosed using DSM-III-R or DSM-IV crite-
ria on the basis of the Diagnostic Interview for Genetic
Studies (DIGS) and complementary data from the medi-
cal files. Most of these subjects had previously participated
in a pharmacogenetic study with a detailed evaluation of
therapeutic response to medication [14]. For the family-
based study, subjects and their families were recruited
from mental health facilities in Montreal, Ottawa, Hun-
gary, France, and Tunisia. A total of 281 complete (n =
182) and incomplete (n = 99) triads were genotyped
(Table 1).
Case/control analysis was conducted exclusively with sub-
jects from Montreal, Ottawa and Tunisia since unaffected
control subjects were not available for analysis from Hun-
gary and France. This step was undertaken to minimize
any effects arising due to population stratification. Unre-
lated cases (n = 289) and controls (n = 273) were used for
the case-control analysis. The cases included (Table 2): (1)
unrelated probands (n = 123), recruited from Montreal,
Ottawa, and Tunisia, who were included in the family-
based analysis. Only probands from families having one
affected individual were included for this case-control
analysis (Table 1), in order to avoid introducing bias by
selecting between multiple affected individuals from a
single family; (2) subjects (n = 166) recruited from mental
health facilities in the three regions, for whom parent
DNA samples were not available (termed "isolated
cases"). Table 2 gives a detailed break-up of the ethnicities
of the cases and controls.
Controls were recruited in Montreal, Ottawa and Tunisia,
either by newspaper advertisement or random sampling
from a downtown population or open advertisement
among the employees of the hospitals where the studies
were conducted. Each control subject was evaluated by a
trained clinician using the Structured Clinical Interview
for DSM-IV, Non-patient edition (SCID-NP) to ensure
that the individual did not have an ongoing or previous
psychiatric illness. Written, informed consent was
obtained from each patient and non-affected subject prior
to beginning the study. The research protocol and the con-
sent forms were approved by the Ethics Committee of
each Institutional Review Board.
Genotyping
Genomic DNA was extracted from peripheral blood using
standard procedures. The trinucleotide repeat within
SMARCA2 was amplified by polymerase chain reaction
(PCR) using the following primers: forward-
5'TGCAGTCCAGGGGAAAAGGACGTT3', reverse-
5'CCCGGGCCAGATGGTCTGTTGTAG3'. The forward
primer was fluorescent labeled with 6-FAM™ (Applied
Biosystems). A 15 µl PCR reaction, containing 10 ng DNA,
2.5 mM MgCl2, 0.25 mM of each dNTP, 0.33 µM of each
primer, and 0.6 units Taq Polymerase was carried out.
After initial denaturation at 94°C for 5 minutes, 35 cycles
were carried out at 94°C for 1 min, 61.3°C for 1 min,
72°C for 1 min, followed by a final extension at 72°C for
30 min.
After verification of the PCR amplification by agarose gel
electrophoresis, 0.5 µls of each sample was mixed with 0.3
µls size standard (GeneScan™ 500 LIZ™) and 9.2 µls
deionized formamide (Applied Biosystems), denatured at
95°C for 5 minutes, and placed on ice. Each 96-well plate
was analyzed using the ABI PRISM® 3100 Genetic Analyzer
and GeneScan v3.7. The sizes of the DNA fragments were
obtained in comparison to the DNA standard using Gen-
otyper®  Software v3.7. The most frequently occurring
allele, corresponding to a size of 181 bp (obtained using
Genotyper®) was designated "0". The sizes of each of the
respective alleles increased or decreased proportionately
by 3 bps i.e. alleles -1, and +1 had sizes of 178 and 184
bps respectively.
Statistical analysis
The Transmission Disequilibrium Test [15] was con-
ducted using the FBAT (Family-Based Association Tests)
program [16]. Allele frequencies in affected subjects and
non-affected controls were compared using the Pearson
chi-square (χ2) statistic in Statistica®. Statistical signifi-
cance was established at p < 0.05.
Table 5: Transmission Disequilibrium Test and FBAT analysis
Allele Allele Frequency No. of informative triads Z statistic p
-1 0.12 53 -2.12 0.034
0 0.85 67 1.65 0.099
+1 0.03 23 0.35 0.72Publish with BioMed Central    and   every 
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DIGS – Diagnostic Interview for Genetic Studies
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PCR – polymerase chain reaction
SCID-NP – Structured Clinical Interview for DSM-IV,
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SMARC – SWI/SNF-related, matrix-associated, actin-
dependant regulator of chromatin
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